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MicroarrayThe physiological function of the human DNA polymerase θ (pol θ) is still unclear despite its in vitro translesion
synthesis capacity duringDNA damage repair process. However this DNA polymerase is always present along the
cell cycle in the absence of replication stress and DNA damage. Is there a different molecular function?We pres-
ent the genomic data of replication timing in depleted pol θ cells (GSE49693) and in cells overexpressing pol θ
(GSE53070) indicating that Pol θ holds a novel role in the absence of external stress as a critical determinant of
the replication timing program in human cells.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).SpeciﬁcationsOrganism/cell
line/tissueHomo sapiens
RKO cell lines for depletion of pol θ
MRC5-SV cell lines for overexpression of pol θSex Male or female if applicable
Sequencer or
array typeGPL10123 Agilent-022060 SurePrint G3 Human CGH
Microarray 4 × 180 KData format Raw data
Experimental
factorsEarly S-phase versus Late S-phaseExperimental
featuresTwo-condition experiments, siRNA control vs. siRNApol θ cells
and overexpressed polθ cells versus control cells. Biological
replicates: 2 control replicates, 2 transfected replicates.Direct link to deposited datahttp://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE49693.
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53070.
Experimental design, materials and methods
Cell transfection
Pol θ depleted cells
RKO cells were transfected with siRNA targeting POL θ by two inde-
pendent pools of siRNA:
– POLQ-1 siRNA: ON-TARGET plus smart pool of 4 POLQ siRNA from
Dharmacon (Thermo Fisher Scientiﬁc, Waltham, USA): CCUUAAGAMR7592, CNRS and University
, France.
. Hoffmann).
. This is an open access article underCUGUAGGUACU, ACACAGUAGGCGAGAGUAU,CGACUAAGAUAGAU
CAUUU,CAAACAACCCUUAUCGUAAA
– siRNA POLQ-2: ON-TARGET plus smart pool of 4 POLQ siRNA from
Dharmacon: UCAGAGGGAUGGAGCUAAU, GAGAUUACCCUUUCAC
CUA, CAAUUUUACAGUACGGAAA, UGAUAGAUUAGCCUAGUA
RKO cells were transfected with siRNA Luciferase as control (5′-
CGUACGCGGAAUACUUCGAdTdT-3′ from Sigma-Aldrich, Saint-Louis,
USA).
Cells overexpressing Pol θ
MRC5-SV ﬁbroblasts were transfected with the pol θ overexpression
vector. The design and construction of the pol θ expression vector as
well as the overexpressing Pol θ cells and their isogenic controls were
previously described [1].
Transfections were performed by using Lipofectamine 2000 trans-
fection reagent (Invitrogen, Carlsbad, USA) at the ﬁnal concentration
of 50 nM following the manufacturer's suggestions. Transfection medi-
um was changed after 8 h to complete medium.
Growth protocol
RKO cells: The human RKO cell line was purchased from ATCC and
grown in DMEM with GlutaMAX I, high-glucose, sodium pyruvate
(Gibco, Life Technologie), supplemented with 10% fetal bovine serum
(Lonza), penicillin (100 U ml−1) and streptomycin (100 μg ml−1)
(Gibco) at 37 °C, 5% CO2 and 5% O2 (standard culture conditions).
MRC5-SV: The Human MRC5-SV cell line was purchased from ATCC
and grown inModiﬁed EagleMediumwith GlutaMAX™ I, High glucose,the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fetal Bovine Serum (Lonza), penicillin (100 U/ml) and streptomycin
(100 μg/ml) (Gibco) at 37 °C, 5% CO2 and 5% O2 (standard culture
conditions).
BrDU treatment
Cells were incubated with BrdU (50 μM) for 1 hour, collected,
washed three times in PBS, then ﬁxed in 75% ethanol, and stored at
−20 °C. Fixed cells were ﬁrst re-suspended in PBS with RNAse (0.5
mg/ml) and thenwith propidium iodide (50 μg/ml) a 30min incubation
at room temperature before the cell sorting.
Cell sorting
80,000 cellswere sorted in two fractions S1 and S2 using INFLUX500
(Cytopeia purchased by BD Biosciences) corresponding to early and late
fractions respectively (Fig. 1).
DNA extraction
A proteinase K treatment (0.2 mg/ml) was performed in both frac-
tions in lysis buffer (50 mM Tris pH = 8; 10 mM EDTA; 300 mM
NaCl) during 2 h at 65 °C. DNA is protected from light. Then, tRNA was
added (50 ng/μl) and a phenol-chloroform extraction followed by an
ethanol precipitation was performed. The pellet is resuspended in
100 μl of Tris buffer (10 mM). Then the two fractions were sonicatedFig. 1.Different proﬁles of FACS analysis for each cell lines used in our experiments. A: RKO cell
SV control cell line. D: MRC5-SV cell line overexpressing pol θ. Blue fraction corresponds to ea
assigned S2.in order to obtain fragments between 500 and 1000 bp. DNA is dena-
tured at 95 °C 5 min and then kept on ice during 10 min.
Neo-synthesized DNAwas immunoprecipitated with BrdU antibod-
ies (10 μg, Anti BrdU Pure, BD Biosciences, # 347580) by an
immunoprecipitated indirect method. Neo-synthesized DNA was incu-
bated overnight at 4 °C with 10 μg of BrdU antibod, then incubated dur-
ing 2 h with magnetic beads prepared as mentioned by the
manufacturer (Adamtech; ChIP adambeads #04342). Beads were
washed with different buffers (IP buffer: Tris pH = 8 10 mM; EDTA
1 mM; NaCl 150 mM, Triton ×100 0.5%; BufferB: Tris pH = 8 20 mM;
EDTA 2mM; NaCl 250mM; Triton ×100 0.25%). Beads are resuspended
in Tris buffer (10mM). The reversion stepwas then performedwith SDS
(1%) and 0.5 mg of proteinase K at 65 °C overnight. Neo-synthesized
DNA is puriﬁed by a pheno-chloroform treatment and an ethanol pre-
cipitation. Pellet is resuspended in Tris buffer (pH= 8, 10mM). To con-
trol the quality of enrichment of early and late fractions in S1 and S2,
qPCR was performed (Fig. 2A, B, C, D) with CAV2 oligonucleotides as
early control (GGCTTGGAGTTTCAACAGGA and CGCAGGTACGAGTCAC
AACA) and with bgGRM8 oligonucleotides as late control (GGGAAGGA
AATGCAAGACAA and AATTTGGCTGCTTAGCATGG) and normalized
with amplicon from neo-synthesized mitochondrial DNA (AACCGCTA
RGTATTTCGTACA and GGTTGATTGCTGTACTTGCTTG).
WGA ampliﬁcation and labeling
Microarray hybridization requires a minimum amount of 500 ng of
DNA. To obtain sufﬁcient speciﬁc immunoprecipitated neo-synthesizedline transfectedwith the siRNA LUC. B: RKO cell line transfectedwith siRNA pol θ. C: MRC5-
rly replicated fraction assigned S1. Orange fraction corresponds to late replicated fraction
Fig. 2. Quality control of neo-synthesized DNA isolation by quantitative PCR before WGA ampliﬁcation (A, B, C, D) and after WGA ampliﬁcation (E, F, G, H). Oligo Cav2 permits to control
early replicated enrichment and Brgm8, late replicated enrichment. S1 corresponds to early replicated fraction isolated by cell sorting, S2 to late replicated fraction. A and E assign RKO
siRNA LUC, B and F, RKO siRNA pol θ. C and G call MRC5-SV control cell line, D and H, MRC5-SV cell line overexpressing pol θ.
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sure that this step does not introduce bias, a qPCR after WGA was per-
formed to conﬁrm the speciﬁc enrichment in each fraction S1 and S2
(Fig. 2E, F, G, H). After ampliﬁcation, early and late neo-synthesized
DNA fractions were labeled with Cy3 and Cy5 ULS molecules (Genomic
DNA labeling Kit, Agilent) as recommended by the manufacturer.
Hybridization protocol
The hybridization was performed according to the manufacturer's
instructions on 4 × 180 K human microarray (SurePrint G3 Human
CGH Microarray Kit, 4 × 180 K, AGILENT Technologies, genome refer-
ence Hg18) that covers the whole genome with one probe every
13 Kb (11 KB in RefSeq sequences).
Scan protocol
Microarrayswere scannedwith an Agilent's High-Resolution C Scan-
ner using a resolution of 2 μm and the autofocus option.
Data processing
Feature extraction was performed with the Feature Extraction 9.1
software (Agilent technologies). For each experiment, the raw data
sets were automatically normalized by the Feature extraction software
using the CGH_1105_oct12 FE protocol browser. Analysis was per-
formed with the Agilent Genomic Workbench 5.0 software. The log2-
ratio timing proﬁles (Fig. 3) were smoothed using the Triangular Mov-
ing Average option of the Agilent Genomic Workbench 5.0 software
with the Triangular algorithm and 500-kb windows.Fig. 3.Microarray proﬁles of the timing of replication on chromosome 6: 1 997 799–14 527 48
Dashed lines: RKO siRNA polQ. Arrows indicate the main changes in the timing of replication.The algorithm from CGH applications of the Agilent GenomicWork-
bench 5.0 software was used in order to determine the replication do-
mains (early and late domains) in Pol θ-depleted RKO cells and in Pol
θ-overexpressing MRC5-SV cells. The aberration detection algorithms
associated with the Z-score and with a threshold of 1.8 deﬁne the
boundaries and magnitudes of the regions of DNA loss or gain corre-
sponding to the late and early replicatingdomains respectively (Regions
with a positive log-ratio is replicated early and late when the log-ratio is
negative).
Basic analysis
A comparison was conducted between early and late domains be-
tween each cell lines. As mentioned by Hiratani et al. [2], two major
changes can be characterized. The intersection between CTRL siRNA
late and POLQ-1 siRNA early intervals will reveal segments that are rep-
licated earlier due to the depletion of Pol θ. Conversely with CTRL siRNA
early versus POLQ-1 siRNA late domains, intervals that are replicated
later will be characterized. Similarly, the intersection between MRC5-
CTRL late andMRC5-overexpressing Pol θ early intervals will reveal seg-
ments that have become earlier by the overexpression of Pol θ, and con-
versely with MRC5-CTRL early versus MRC5-overexpressing Pol θ late
domains, intervals that are replicated late will be characterized. The in-
tersection was performed with the Intersection GALAXY tools (Operate
on genomic intervals, https://main.g2.bx.psu.edu/).
Discussion
Here we put in evidence a new function of Pol θ because a change in
expression of this protein disturbs the replication timing program.7 (12.5 Mb, hg18); Two replicates for each cell line. Continuous lines: RKO siRNA control.
Black arrows: Early to late (EtoL), gray arrows: late to early (LtoE).
93G. Baldacci et al. / Genomics Data 3 (2015) 90–93These data and other evidences are published recently and demonstrate
the molecular role of Pol θ in DNA replication [3]. This novel Pol θ func-
tion could be particularly important within the context of cancer be-
cause in colon, breast and lung cancers, a high pol θ expression was
observed and associated with poor clinical outcome of patients [1,4–7].
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